LPH-5
Psychiatric disorders (e.g., Depression)
Phase 1Active
Key Facts
About Lophora
Lophora is a Danish private biotech company pioneering next-generation psychedelic-inspired therapeutics for central nervous system disorders. Its core technology is a rational drug design platform focused on creating selective 5-HT2A receptor agonists with optimized drug-like properties. The company's lead asset, LPH-5, has successfully completed Phase I trials, positioning it as a potential rapid-acting, non-hallucinogenic treatment for major depressive disorder and other conditions. Lophora is backed by notable Danish public funders and experienced biotech investors.
View full company profile